로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Licensing > BPR202201

CD19+CD37 CAR-T

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: CD19+CD37 CAR-T
    Indications: NHL, Leukemia
    Research phase: Pre-clinical
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.


    (1). CD19 is expressed on nearly all B-cell malignancies: including ALL, CLL, many NHL (>95%).
    (2). CD37 is expressed on mature B cells ,but it expressed at very low levels in T cells, macrophages, monocytes and dendritic cells.


    2. High affinity.


    3. High efficacy in-vitro.


    (1). Specific cell killing activity and high cytokine production on CD37 positive cancer cell.



    Specific cell killing activity and high cytokine production on CD37 positive cancer cell


    (2). Specific cell killing activity and high cytokine production on CD19 positive cancer cell.



    Specific cell killing activity and high cytokine production on CD19 positive cancer cell


    4. CD19+CD37 CAR-T Significantly reduces Raji tumor growth, prolongs survival in mice.



    CD19+CD37 CAR-T Significantly reduces Raji tumor growth, prolongs survival in mice

  • Project Introduction

    1. Asset type: CD19 + CD37 CAR-T

    2. Indication: NHL, Leukemia

    3. Research phase: Pre-clinical

    4. Cooperation demands: License-out or co-development

    5. Research progress:

    1) Complete the CD19+CD37 CAR-T Screening.

    2) CD19+CD37 CAR-T activity in vitro and in vivo showed the high killing activity against many CD19 or CD37 positive cancer cells.

    3) CD19+CD37 CAR-T co-incubated with Hela CD19+ cells secreted less IFN-γ than CD19 CAR-T, thus may low risk of “cytokine storm”.

    4) CD19+CD37 CAR-T significantly prolonged the survival of tumor-bearing mice. After 7 weeks of treatment, no mice died.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments